Breaking News

Tweet TWEET

Oxygen Biotherapeutics to Present at Aegis Capital Healthcare Conference in Las Vegas on September 27, 2013

  Oxygen Biotherapeutics to Present at Aegis Capital Healthcare Conference in
  Las Vegas on September 27, 2013

Aegis Capital Healthcare Conference 2013

Business Wire

MORRISVILLE, N.C. -- September 19, 2013

Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a developer of oxygen-carrying
therapeutics, announced today that the Company’s Interim CEO, President and
CFO Michael Jebsen, will participate in the Aegis Capital Healthcare
Conference in Las Vegas from September 25 – 28, 2013.

Michael Jebsen is scheduled to present an overview of Oxygen Biotherapeutics
to investors on Friday, September 27th at 8:30 am PT.

Investors or journalists may request a one-on-one meeting with Oxygen
Biotherapeutics’ management by contacting Robert Haag at 1-866-976-IRTH (4784)
or oxbt@irthcommunications.com.

Oxygen Biotherapeutics was recently issued a new patent for its PFC-based
products for topical delivery to the skin for dermatologic conditions and
wound care for indications of psoriasis and pruritus. The Company is currently
conducting Phase IIb trials for its proprietary perfluorocarbon (PFC)
therapeutic oxygen carrier called Oxycyte® for the treatment of severe
non-penetrating traumatic brain injury. The Company’s platform technology
addresses multiple healthcare markets valued at well over $1 billion. Oxygen
Biotherapeutics maintains research contracts with the U.S. military and owns
or exclusively licenses 9 patents issued and pending.

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is developing medical products that efficiently
deliver oxygen to tissues in the body. The company has developed a proprietary
perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte^®that is
currently in clinical and preclinical studies for intravenous delivery for
indications such as traumatic brain injury, decompression sickness and stroke.
The company is also developing PFC-based creams and gels for topical delivery
to the skin for dermatologic conditions and potentially wound care. In
addition, the Company has commercialized its Dermacyte^®line of skin care
cosmetics for the anti-aging market. Dermacyte is now out-licensed to Valor
Cosmetics of Switzerland.

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company
that involve risks and uncertainties and reflect the company’s judgment as of
the date of this release. The forward-looking statements are subject to a
number of risks and uncertainties, delays in new product introductions and
customer acceptance of these new products, and other risks and uncertainties
as described in our filings with the Securities and Exchange Commission,
including in the current Form 10-Q filed on September 17, 2013, and our annual
report on Form 10-K filed on June 26, 2013, as well as other filings with the
SEC. The company disclaims any intent or obligation to update these
forward-looking statements beyond the date of this release. This caution is
made under the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.

Contact:

Oxygen Biotherapeutics Investor and Media Relations
Robert Haag, 1-866-976-IRTH (4784)
Managing Director
IRTH Communications
oxbt@irthcommunications.com